Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.58 |
| ▸ | RARA | P10276 | 17/20 | 0.58 |
| ▸ | RARG | P13631 | 16/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428466 | 0.93 | RARB (0.48) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6427908 | 0.90 | RARB (0.50) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6262562 | 0.88 | RARA (0.75) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6258858 | 0.84 | RARA (0.58) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6259665 | 0.82 | RARB (0.63) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6262565 | 0.82 | RARA (0.72) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6428467 | 0.81 | RARA (0.57) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL7635593 | 0.80 | RARB (0.62) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6398148 | 0.80 | RARB (0.62) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6240831 | 0.79 | RARA (0.76) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287327-B1 | In vitro anti tumor compound toxicity screening methods | CEETOX INC (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906057-B1 | Methods for modulating FXR receptor activity | ALLERGAN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | RARB 3345/4885RARA 2919/4885RARG 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.